drugset / Trial / NCT05823285
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.
Timeline
- Start
- 2023-03-22
- Primary completion
- 2025-06-15
- Completion
- 2027-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLS31903 | Unknown | 0.01 ug/kg | — |
| Subject | QLS31903 | Unknown | 2.16 ug/kg | — |